|
General Information
|
|
|
Product
|
Parkin Peptide
|
|
Verified Applications
|
Immunodepletion, Immunocompetition
|
|
Peptide Description
|
Synthetic peptide
|
|
Accession #
|
GenBank: BAA25751.1
|
|
Physical Properties
|
|
|
Quantity
|
250 µg
|
|
Volume
|
100 µl
|
|
Form
|
Antigenic Blocking Peptide
|
|
Storage
|
-20⁰C for long term storage
|
|
Application Protocol
|
|
Competition/Depletion assay
|
Refer to competition assay protocol
|
|
Protein
|
|
Uniprot #
|
O60260
|
|
Overview
|
Acts within a multiprotein E3 ubiquitin ligase complex, by catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins. It also participates in the removal and/or detoxification of proteins that are abnormally folded or damaged.
|
|
Molecular Function
|
Ligase, Chaperone binding, Protein kinase binding
|
|
Subcellular Location
|
Cytoplasm, Nucleus, Endoplasmic reticulum, Mitochondrion
|
|
Expression
|
Expressed highly in the brain, and is also expressed in the heart, testis and skeletal muscle. Expression is down-regulated or absent in tumor biopsies and in the brain of PARK2 patients.
|
|
Structure
|
Forms E3 ubiquitin ligase complex with UBE2L3 or UBE2L6. Binds to C2A and C2B domains of SYTqq and interacts and regulates the turnovers of SEPT5.
|
|
Alternative Nomenclature
|
AR JP antibody
E3 ubiquitin ligase antibody
FRA6E antibody
LPRS 2 antibody
PARK 2 antibody
Parkin 2 antibody
Parkinson disease (autosomal recessive juvenile) 2 antibody
Parkinson protein 2, E3 ubiquitin protein ligase (parkin) antibody
PDJ antibody
PRKN 2 antibody
Ubiquitin E3 ligase PRKN antibody
|
| |
|
Parkin Antibody
Parkin Antibody FITC
Parkin Antibody BIOTIN
Parkin Positive Control
